Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

Conditions

• Psoriatic Arthritis

Eligibility Criteria

Sex

ALL

Age

18 Years - 80 Years

Healthy Volunteers

Not accepted

Interventions

• Tulisokibart — DRUG
  Subcutaneous administration
• Placebo — DRUG
  Subcutaneous administration

Study Details

Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen PsA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Key Dates

Start date

Apr 20, 2026

Status verified

Jun 2026

Primary completion

Aug 13, 2027

Completion

Jan 11, 2030

Study Design

Enrollment

140 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: High-Dose Regimen
  Participants receive a high dose of tulisokibart.
• Experimental: Medium-Dose Regimen
  Participants receive a medium dose of tulisokibart.
• Experimental: Low-Dose Regimen
  Participants receive a low dose of tulisokibart and are rerandomized at Week 16 to a medium or high dose of tulisokibart.
• Placebo Comparator: Placebo Regimen
  Participants receive a matched placebo dose and are rerandomized at Week 16 to a medium or high dose of tulisokibart.

Primary Outcome Measure

Percentage of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 16 [ Time Frame: Week 16 ]

Central Contacts

• Toll Free Number
  1-888-577-8839
  [email protected]

Locations (15)

Find similar trials in Sun City, AZ

Related Studies

• Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
  Recruiting · University of California, San Diego · La Jolla, California
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  PHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
• Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
  Recruiting · M.D. Anderson Cancer Center · Houston, Texas
• Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
  PHASE3 · Recruiting · University of Pennsylvania · Loxahatchee Groves, Florida